Clinical characteristics (n = 44)
| | | |
Age, years
| |
64.2 ± 14.5
|
22 to 92
|
Sex (male)
|
29 (65.9)
| | |
Dialysis vintage, months
| |
43.8 ± 38.3
|
3 to 183
|
Etiology of ESKD
| | | |
Diabetes mellitus
|
11 (25.0)
| | |
Renovascular disease
|
14 (31.8)
| | |
Other
|
19 (43.2)
| | |
Cardiovascular disease
|
14 (31.8)
| | |
Peripheral vascular disease
|
17 (38.6)
| | |
Cerebrovascular disease
|
6 (13.6)
| | |
History of fracture
|
17 (38.6)
| | |
Non-smoker
|
17 (38.6)
| | |
Vitamin K status
| | | |
Phylloquinone concentration, nmol/L (n = 44)
| |
1.25 ± 1.17
|
0 to 5.3
|
%ucOC (n = 42)
| |
24.5 ± 15.4
|
5.2 to 63.1
|
PIVKA-II, nmol/L (n = 44)
| |
3.98 ± 2.51
|
1.5 to 14.5
|
Laboratory measures
| | | |
Phosphate, mmol/L (n = 43)
| |
1.49 ± 0.38
|
0.61 to 2.96
|
Calcium, ionized, mmol/L (n = 43)
| |
1.17 ± 0.08
|
0.97 to 1.36
|
Parathyroid hormone, pmol/L (n = 43)
| |
38.7 ± 39.4
|
0.9 to 220.1
|
Albumin, g/L (n = 43)
| |
40.4 ± 3.2
|
32 to 48
|
Total cholesterol, mmol/L (n = 43)
| |
3.74 ± 0.86
|
2.1 to 6.3
|
LDL cholesterol, mmol/L (n = 41)
| |
1.62 ± 0.63
|
0.4 to 3.1
|
HDL cholesterol, mmol/L (n = 43)
| |
1.30 ± 0.35
|
0.7 to 2.3
|
Triglycerides, mmol/L (n = 43)
| |
1.75 ± 1.23
|
0.8 to 5.6
|
Kt/V (n = 44)
| |
1.52 ± 0.35
|
0.71 to 2.23
|
URR (n = 44)
| |
0.73 ± 0.07
|
0.50 to 0.88
|